FindTrial
Sign In

Vascular function and Antiplatelet effects on switching from Clopidgrel to Prasugrel in chronic phase after percutaneous coronary intervention

Vascular function and Antiplatelet effects on switching from Clopidgrel to Prasugrel in chronic phase after percutaneous coronary intervention - Switch-Pras study

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000023756
Enrollment
100
Registered
2016-09-01
Start date
2015-06-30
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The patients on DAPT after PCI who underwent follow-up coronary angiography

Interventions

Clopidgrel with Aspirin group Aspirin is 81mg X1 Clopidgrel is 75mg X1 Prasugrel with Aspirin group Aspirin is 81mg X1 Prasugrel is 3.75mg X1

Sponsors

Department of Cardiovascular Medicine,Dokkyo Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1:The patients on DAPT after PCI who underwent follow-up coronary angiography 2:Patients agreening with this study after informed consent

Exclusion criteria

Exclusion criteria: 1:Ptients who has high risk for bleeding 2:Patients with heart Valve Disease and congenital heart disease 3:Patients with cerebrovascular disease 4:Patients who have infection or Inflammatory disease 5:Patients with malignant neoplasm 6:CKD <G4 eGFR<30(ml/min/1.7m2) 7:Patients with allergy against thienopyridines 8:Patients undergoing anticoagulation therapy 9:Patients who are not suitable for this study

Design outcomes

Primary

MeasureTime frame
The rate of change on PRU from baseline to observation point(6M+-3M) between Clopidgrel with Aspirin and Prasugrel with Aspirin—

Secondary

MeasureTime frame
1:The effect of CYP2C19 polymorphism against the PRU from baseline to observation point between Clopidgrel with Aspirin and Prasugrel with Aspirin 2:Quantitative change on FMD from baseline to observation point between Clopidgrel with Aspirin and Prasugrel with Aspirin 3:Quantitative change on RHI from baseline to observation point between Clopidgrel with Aspirin and Prasugrel with Aspirin 4:Quantitative change and rate of change on Inflammatory biomarkers from baseline to observation point between Clopidgrel with Aspirin and Prasugrel with Aspirin 5:Quantitative change on CD34+/CD133+/CD45low cells from baseline to observation point between Clopidgrel with Aspirin and Prasugrel with Aspirin—

Countries

Japan

Contacts

Public ContactMasashi Sakuma

Dokkyo Medical University Cardiovascular Medicine

masakuma@dokkyomed.ac.jp0282-86-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026